The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab (Bev) with or without erlotinib as maintenance therapy, in patients (pts) with metastatic colorectal cancer (mCRC): Exploratory analysis according to KRAS status in the gercor DREAM phase III trial.
Benoit Samson
No relevant relationships to disclose
Christophe Tournigand
Honoraria - Roche
Werner Scheithauer
No relevant relationships to disclose
Gérard Lledo
No relevant relationships to disclose
Frédéric Viret
No relevant relationships to disclose
Thierry André
Honoraria - Roche
Jean François Ramée
No relevant relationships to disclose
Nicole Tubiana-Mathieu
No relevant relationships to disclose
Jérôme Dauba
No relevant relationships to disclose
Olivier Dupuis
No relevant relationships to disclose
Yves Rinaldi
No relevant relationships to disclose
May Mabro
No relevant relationships to disclose
Nathalie Aucoin
No relevant relationships to disclose
Ahmed Khalil
No relevant relationships to disclose
Jean Latreille
No relevant relationships to disclose
Christophe Louvet
No relevant relationships to disclose
David Brusquant
No relevant relationships to disclose
Franck Bonnetain
No relevant relationships to disclose
Benoist Chibaudel
No relevant relationships to disclose
Aimery De Gramont
Honoraria - Roche